NIMH Drug Trials for Schizophrenia

J Clin Psychiatry. 2019 Jan 15;80(1):18com12597. doi: 10.4088/JCP.18com12597.

Authors

E Fuller Torrey^{1

2}, Robert H Yolken³, H Richard Lamb⁴

Affiliations

¹ Stanley Medical Research Institute, 10605 Concord St, Suite 206, Kensington, MD 20895. torreyf@stanleyresearch.org.
² Stanley Medical Research Institute, Kensington, Maryland, USA.
³ Stanley Laboratory of Developmental Neurovirology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
⁴ Department of Psychiatry and Behavioral Science, University of Southern California, Los Angeles, California, USA.

PMID: 30677268
DOI: 10.4088/JCP.18com12597

No abstract available

MeSH terms

Antipsychotic Agents / pharmacology*
Behavioral Research / standards*
Biomedical Research / standards*
Drug Discovery* / methods
Drug Discovery* / organization & administration
Humans
National Institute of Mental Health (U.S.)
Quality Improvement
Schizophrenia / drug therapy*
United States

Substances

Antipsychotic Agents